Prolactin-Secreting Tumors and Hypogonadism in 22 Men

Prolactin-Secreting Tumors and Hypogonadism in 22 Men. Carter, John N., John E. Tyson, George Tous, Stuart Van Vliet, Charles Faiman, and Henry G. Friesen. 299.16 (1978): 847-52.


We studied 22 men with prolactin-secreting pituitary tumors and hypogonadism. Twenty complained of impotence, nine had visual impairment, and three experienced galactorrhea. None of the 17 patients undergoing operation or radiotherapy, or both, were subsequently normoprolactinemic. In all 13 patients treated with bromocryptine major clinical improvement was associated with a decrease in serum prolactin levels and in nine with an increase in serum testosterone. Two patients receiving testosterone replacement therapy showed improved potency only after bromocryptine was administered. The results indicate that hyperprolactinemia frequently induces hypogonadism in men, that bromocryptine ameliorates symptoms of disease previously unchanged by operation or radiotherapy, and that the impotence observed may not be solely the result of hypogonadism.

Hyperprolactinemic male infertility

Hyperprolactinemic Male Infertility. Segal, S., WZ Polishuk, and David M. Ben. 27.12 (1976): 1425-427.


Serum prolactin was studied in 25 fertile and 127 infertile men. The latter included 91 oligospermic, 27 azoospermic, and 9 hypogonadotropic hypogonadal men. The mean prolactin level in all three groups of infertile men was significantly above that of the fertile group. There was no correlation among serum levels of follicle-stimulating hormone, luteinizing hormone, sperm count, and serumprolactin values. Hyperprolactinemia was found in five patients (two oligospermic, one azoospermic, and two hypogonadotropic hypogonadal men). Bromocriptine, 2.5 mg twice daily, suppressedhyperprolactinemia. In one man with hyperprolactinemic oligospermia, treatment with bromocriptineyielded significant improvement in sperm count (to normal values).